HIGHLIGHTS
SUMMARY
Indeed, new randomized trials do not seem to show an overall survival (OS) benefit for patients undergoing surgery plus systemic therapy versus systemic therapy alone. Pe- 4 of 9 trelli et_al, in a meta-analysis involving twelve studies with a total of 39,953 patients, evaluated the prognostic role of CN in advanced mRCC disease treated with molecular agents, reporting a lower mortality risk (by more than 50%) in patients treated with CN and targeted therapy compared to targeted therapy alone. After 50.9 months of follow-up, the ITT analysis showed a median . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.